Literature DB >> 25056269

Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates.

David M McDonald1, Brendan L Wilkinson, Leo Corcilius, Morten Thaysen-Andersen, Scott N Byrne, Richard J Payne.   

Abstract

We describe herein the synthesis and immunological evaluation of self-adjuvanting mucin 1 (MUC1)-macrophage activating lipopeptide 2 (MALP2) (glyco)peptide vaccine candidates. Vaccine constructs were shown to induce high titres of class-switched IgG antibodies in C57BL/6 mice after four immunisations despite the lack of a helper T cell epitope.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25056269     DOI： 10.1039/c4cc03510k

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  11 in total

Review 1.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

2.  Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Authors:  Nitin T Supekar; Vani Lakshminarayanan; Chantelle J Capicciotti; Anju Sirohiwal; Cathy S Madsen; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2017-11-30       Impact factor: 3.164

3.  Synthetic protein conjugate vaccines provide protection against Mycobacterium tuberculosis in mice.

Authors:  Cameron C Hanna; Anneliese S Ashhurst; Diana Quan; Joshua W C Maxwell; Warwick J Britton; Richard J Payne
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-26       Impact factor: 12.779

4.  A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.

Authors:  Zhifang Zhou; Guochao Liao; Satadru S Mandal; Sharad Suryawanshi; Zhongwu Guo
Journal:  Chem Sci       Date:  2015-09-22       Impact factor: 9.825

Review 5.  Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines.

Authors:  Md Kamal Hossain; Katherine A Wall
Journal:  Vaccines (Basel)       Date:  2016-07-26

Review 6.  Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.

Authors:  Renata Kowalczyk; Paul W R Harris; Geoffrey M Williams; Sung-Hyun Yang; Margaret A Brimble
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

7.  The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.

Authors:  Yonghui Liu; Zhaoyu Wang; Fan Yu; Mingjing Li; Haomiao Zhu; Kun Wang; Meng Meng; Wei Zhao
Journal:  Int J Nanomedicine       Date:  2021-01-14

Review 8.  Synthetic self-adjuvanting glycopeptide cancer vaccines.

Authors:  David M McDonald; Scott N Byrne; Richard J Payne
Journal:  Front Chem       Date:  2015-10-23       Impact factor: 5.221

Review 9.  Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.

Authors:  Qingjiang Li; Zhongwu Guo
Journal:  Molecules       Date:  2018-06-29       Impact factor: 4.411

10.  Going Native: Synthesis of Glycoproteins and Glycopeptides via Native Linkages To Study Glycan-Specific Roles in the Immune System.

Authors:  Mikkel H S Marqvorsen; Can Araman; Sander I van Kasteren
Journal:  Bioconjug Chem       Date:  2019-10-18       Impact factor: 4.774
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.